Cancer drug hope raises Genmab's spirits after legal defeat

Biotech firm Genmab and partner Abbvie have delivered promising topline data from their shared drug hope epcoritamab, a bone marrow cancer treatment. An important validation for Genmab, assesses an analyst, as the company recently lost an important legal battle.

Photo: Joost Melis / Genmab / PR

The show must go on, as the saying goes, which is also true for the biotech sector.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs